Burixafor hydrobromide is primarily utilized in the field of hematology and stem cell transplantation. It acts as a CXCR4 antagonist, which helps in mobilizing hematopoietic stem cells from the bone marrow into the bloodstream. This mobilization is crucial for the collection of stem cells used in transplants for patients with certain types of cancers, such as non-Hodgkin's lymphoma and multiple myeloma. By facilitating the release of these stem cells, it enhances the efficiency of the apheresis process, making it easier to harvest sufficient quantities for therapeutic use. Additionally, it is being explored for its potential in treating other conditions where stem cell mobilization is beneficial, such as in gene therapy and regenerative medicine applications.